{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:47:57Z","timestamp":1758476877157},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T00:00:00Z","timestamp":1281052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s00384-010-1039-x","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T04:53:38Z","timestamp":1280984018000},"page":"1465-1473","source":"Crossref","is-referenced-by-count":13,"title":["The effect of bevacizumab on colon anastomotic healing in rats"],"prefix":"10.1007","volume":"25","author":[{"given":"Efstathios T.","family":"Pavlidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos D.","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos G.","family":"Symeonidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriakos","family":"Psarras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Koliakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kokona","family":"Kouzi-Koliakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina","family":"Topouridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savas F.","family":"Rafailidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros E.","family":"Pavlidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios N.","family":"Marakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios K.","family":"Sakantamis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,6]]},"reference":[{"key":"1039_CR1","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1007\/s10350-005-0026-8","volume":"48","author":"RR McWilliams","year":"2005","unstructured":"McWilliams RR, Erlichman C (2005) Novel therapeutics in colorectal cancer. Dis Colon Rectum 48:1632\u20131650","journal-title":"Dis Colon Rectum"},{"key":"1039_CR2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/bjs.5624","volume":"93","author":"AD Thornton","year":"2006","unstructured":"Thornton AD, Ravn P, Winslet M et al (2006) Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg 93:1456\u20131463","journal-title":"Br J Surg"},{"key":"1039_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2710.2007.00800.x","volume":"32","author":"I Kr\u00e4mer","year":"2007","unstructured":"Kr\u00e4mer I, Lipp HP (2007) Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 32:1\u201314","journal-title":"J Clin Pharm Ther"},{"key":"1039_CR4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003495-200868040-00009","volume":"68","author":"PL McCormack","year":"2008","unstructured":"McCormack PL, Keam SJ (2008) Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs 68:487\u2013506","journal-title":"Drugs"},{"key":"1039_CR5","first-page":"73","volume":"22","author":"I Kocakova","year":"2009","unstructured":"Kocakova I, Kocak I, Savoboda M et al (2009) Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer. Klin Onkol 22:73\u201376","journal-title":"Klin Onkol"},{"key":"1039_CR6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2146\/ajhp080455","volume":"66","author":"SS Shord","year":"2009","unstructured":"Shord SS, Bressler LR, Tierney LA et al (2009) Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 66:999\u20131013","journal-title":"Am J Health Syst Pharm"},{"key":"1039_CR7","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2007.13.7679","volume":"26","author":"B Gruenberger","year":"2008","unstructured":"Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830\u20131835","journal-title":"J Clin Oncol"},{"key":"1039_CR8","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-07-4081","volume":"14","author":"C Brostjan","year":"2008","unstructured":"Brostjan C, Gebbardt K, Gruenberger B et al (2008) Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenetic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res 14:2065\u20132074","journal-title":"Clin Cancer Res"},{"key":"1039_CR9","unstructured":"Andre T, Tournigand C, Abbas F, et al (French Oncology Research Group) (2007). Anti-angiogenic treatment and colorectal cancer. Bull Cancer 94 Spec No: S211\u2013S219."},{"key":"1039_CR10","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","volume":"28","author":"T Shih","year":"2006","unstructured":"Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779\u20131802","journal-title":"Clin Ther"},{"key":"1039_CR11","first-page":"3619","volume":"25","author":"N Salesi","year":"2005","unstructured":"Salesi N, Bossone G, Veltri E et al (2005) Clinical experience with bevacizumab in colorectal cancer. Anticancer Res 25:3619\u20133623","journal-title":"Anticancer Res"},{"issue":"3","key":"1039_CR12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1677\/ERC-08-0208","volume":"16","author":"N Normanno","year":"2009","unstructured":"Normanno N, Morabito A, De Luca A et al (2009) Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer 16(3):675\u2013702","journal-title":"Endocr Relat Cancer"},{"key":"1039_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/cbt.7.1.5337","volume":"7","author":"N Denduluri","year":"2008","unstructured":"Denduluri N, Yang SX, Berman AW et al (2008) Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther 7:15\u201320","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"1039_CR14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ygyno.2009.04.021","volume":"114","author":"X Tao","year":"2009","unstructured":"Tao X, Sood AK, Deavers MT et al (2009) Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulose cell tumours. Gynecol Oncol 114(3):431\u2013436","journal-title":"Gynecol Oncol"},{"key":"1039_CR15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76\u201382","journal-title":"J Clin Oncol"},{"issue":"7","key":"1039_CR16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrurol.2009.102","volume":"6","author":"EJ Abel","year":"2009","unstructured":"Abel EJ, Wood CG (2009) Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol 6(7):375\u2013383","journal-title":"Nat Rev Urol"},{"key":"1039_CR17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/157016309788488339","volume":"6","author":"A Rossi","year":"2009","unstructured":"Rossi A, Maione P, Colantuoni G et al (2009) Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Curr Drug Discov Technol 6:91\u2013102","journal-title":"Curr Drug Discov Technol"},{"key":"1039_CR18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000224782","volume":"223","author":"HK Seong","year":"2009","unstructured":"Seong HK, Bae JH, Kim ES et al (2009) Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short term effect. Ophthalmologica 223:343\u2013347","journal-title":"Ophthalmologica"},{"key":"1039_CR19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1442-9071.2007.01521.x","volume":"35","author":"MN Chilov","year":"2007","unstructured":"Chilov MN, Grigg JR, Playfair TJ (2007) Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 35:494\u2013496","journal-title":"Clin Experiment Ophthalmol"},{"key":"1039_CR20","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788\u20131795","journal-title":"Br J Cancer"},{"key":"1039_CR21","first-page":"250","volume":"52","author":"JJ Knightly","year":"1962","unstructured":"Knightly JJ, Agostino D, Cliffton EE (1962) The effect of fibrinolysin and heparin on the formation of peritoneal adhesions. Surgery 52:250","journal-title":"Surgery"},{"key":"1039_CR22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10350-006-0727-7","volume":"50","author":"H Konstantinidis","year":"2007","unstructured":"Konstantinidis H, Slavakis A, Ballas K et al (2007) The effect of capecitabine on the healing of colonic anastomosis in rats. Dis Colon Rectum 50:89","journal-title":"Dis Colon Rectum"},{"key":"1039_CR23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clinbiochem.2007.12.008","volume":"41","author":"DH Alamdari","year":"2008","unstructured":"Alamdari DH, Ghayour-Mobarhan M, Tavallaie S et al (2008) Prooxidant\u2013antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease. Clin Biochem 41:375\u2013380","journal-title":"Clin Biochem"},{"key":"1039_CR24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.clinbiochem.2006.10.017","volume":"40","author":"DH Alamdari","year":"2007","unstructured":"Alamdari DH, Paletas K, Pegiou T et al (2007) A novel assay for the evaluation of the prooxidant\u2013antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem 40:248\u2013254","journal-title":"Clin Biochem"},{"key":"1039_CR25","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.freeradbiomed.2005.06.023","volume":"39","author":"DH Alamdari","year":"2005","unstructured":"Alamdari DH, Kostidou E, Paletas K et al (2005) High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein. Free Radic Biol Med 39:1362\u20131367","journal-title":"Free Radic Biol Med"},{"key":"1039_CR26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0009-9120(96)00003-6","volume":"29","author":"GK Reddy","year":"1996","unstructured":"Reddy GK, Enwemeka CS (1996) A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 29:225\u2013229","journal-title":"Clin Biochem"},{"key":"1039_CR27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1091-255X(02)00433-X","volume":"7","author":"DT Efron","year":"2003","unstructured":"Efron DT, Most D, Shi HP et al (2003) Modulation of growth factor and cytokine expression by nitric oxide during rat colon anastomotic healing. J Gastrointest Surg 7:393\u2013399","journal-title":"J Gastrointest Surg"},{"key":"1039_CR28","first-page":"65","volume":"79","author":"P Brasken","year":"1990","unstructured":"Brasken P, Lehto M, Renvall S (1990) Fibronectin, laminin, and collagen types I, III, IV and V in the healing rat colon anastomosis. Ann Chir Gynaecol 79:65\u201371","journal-title":"Ann Chir Gynaecol"},{"key":"1039_CR29","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/bjs.1800780908","volume":"78","author":"P Brasken","year":"1991","unstructured":"Brasken P, Renvall S, Sandberg M (1991) Fibronectin and collagen gene expression in healing experimental colonic anastomoses. Br J Surg 78:1048\u20131052","journal-title":"Br J Surg"},{"key":"1039_CR30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/BF01213309","volume":"32","author":"DK Podolsky","year":"1997","unstructured":"Podolsky DK (1997) Healing the epithelium: solving the problem from two sides. J Gastroenterol 32:122\u2013126","journal-title":"J Gastroenterol"},{"key":"1039_CR31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0899-9007(98)00081-1","volume":"14","author":"MS Murphy","year":"1998","unstructured":"Murphy MS (1998) Growth factors and the gastrointestinal tract. Nutrition 14:771\u2013774","journal-title":"Nutrition"},{"key":"1039_CR32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0039-6109(05)70568-5","volume":"77","author":"FJ Thornton","year":"1997","unstructured":"Thornton FJ, Barbul A (1997) Healing in the gastrointestinal tract. Surg Clin North Am 77:549\u2013573","journal-title":"Surg Clin North Am"},{"key":"1039_CR33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jamcollsurg.2008.10.015","volume":"208","author":"TP Kingham","year":"2009","unstructured":"Kingham TP, Pachter HL (2009) Colonic anastomotic leak: risk factors, diagnosis and treatment. Am Coll Surg 208:269\u2013278","journal-title":"Am Coll Surg"},{"key":"1039_CR34","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.3748\/wjg.15.3901","volume":"15","author":"FJ Guzman-de la Garza","year":"2009","unstructured":"Guzman-de la Garza FJ, Camara-Lemarroy CR, Alarcon-Galvan G et al (2009) Different patterns of intestinal response to injury after arterial, venous or arteriovenous occlusion in rats. World J Gastroenterol 15:3901\u20133907","journal-title":"World J Gastroenterol"},{"issue":"12","key":"1039_CR35","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.bbadis.2009.09.011","volume":"1792","author":"M Fedorova","year":"2009","unstructured":"Fedorova M, Kuleva N, Hoffmann R (2009) Reversible and irreversible modifications of skeletal muscle proteins in a rat model of acute oxidative stress. Biochim Biophys Acta 1792(12):1185\u20131193","journal-title":"Biochim Biophys Acta"},{"key":"1039_CR36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/PPO.0b013e3181570062","volume":"13","author":"JJ Lee","year":"2007","unstructured":"Lee JJ, Chu E (2007) An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 13:276\u2013281","journal-title":"Cancer J"},{"key":"1039_CR37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3748\/wjg.15.449","volume":"15","author":"M Moehler","year":"2009","unstructured":"Moehler M, Sprinzi MF, Abdelfattah M et al (2009) Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 15:449\u2013456","journal-title":"World J Gastroenterol"},{"key":"1039_CR38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","volume":"62","author":"CR Gordon","year":"2009","unstructured":"Gordon CR, Rojavin Y, Patel M et al (2009) A review on bevacizumab and surgical wound healing. An important warning to all surgeons. Ann Plast Surg 62:707\u2013709","journal-title":"Ann Plast Surg"},{"key":"1039_CR39","first-page":"173","volume":"91","author":"FA Scappaticci","year":"2005","unstructured":"Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Clin Oncol 91:173\u2013180","journal-title":"J Clin Oncol"},{"key":"1039_CR40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta- analysis. Lancet Oncol 10:559\u2013568","journal-title":"Lancet Oncol"},{"key":"1039_CR41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/RLI.0b013e31819f1b60","volume":"44","author":"HJ Raatschen","year":"2009","unstructured":"Raatschen HJ, Fu Y, Brasch RC, Pietsch H, Shames DM, Yeh BM (2009) In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol 44:265\u2013270","journal-title":"Invest Radiol"},{"key":"1039_CR42","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1023\/A:1020778001267","volume":"19","author":"V Hsei","year":"2002","unstructured":"Hsei V, DeGuzman GG, Nixon A, Gaudreault J (2002) Complexation of VEGF with bevacizumab decreases VEGF clearance in rats. Pharm Res 19:1753\u20131756","journal-title":"Pharm Res"},{"key":"1039_CR43","first-page":"517","volume":"20","author":"T Mizobe","year":"2008","unstructured":"Mizobe T, Ogata Y, Murakami H, Akagi Y, Ishibashi N, Mori S, Sasatomi T, Shirouzu K (2008) Efficacy of the combined use of bevacizumab and irinotecan as postoperative adjuvant chemotherapy in colon carcinoma. Oncol Rep 20:517\u2013523","journal-title":"Oncol Rep"},{"key":"1039_CR44","doi-asserted-by":"crossref","unstructured":"Igniatovic D, Aasland K, Pettersen M, Sund S, Chen Y, Spasojevic M, Nesgaard JM (2010). Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. Am J Surg 200:270\u2013275","DOI":"10.1016\/j.amjsurg.2009.08.038"},{"key":"1039_CR45","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00384-010-0912-y","volume":"25","author":"K Blouhos","year":"2010","unstructured":"Blouhos K, Pramateftakis MG, Tsachalis T, Kanellos D, Zaraboukas T, Koliakos G, Betsis D (2010) The integrity of colonic anastomoses following the intraperitoneal administration of oxaliplatin. Int J Colorectal Dis 25:835\u2013841","journal-title":"Int J Colorectal Dis"},{"key":"1039_CR46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00384-009-0833-9","volume":"25","author":"M Uludag","year":"2010","unstructured":"Uludag M, Ozdilli K, Citgez B, Yetkin G, Ipcioglu OM, Ozcan O, Polat N, Kartal A, Torun P, Isgor A (2010) Covering the colon anastomoses with amniotic membrane prevents the negative effects of early intraperitoneal 5-FU administration on anastomotic healing. Int J Colorectal Dis 25:223\u2013232","journal-title":"Int J Colorectal Dis"},{"key":"1039_CR47","doi-asserted-by":"crossref","unstructured":"Benjamin B, Hazut O, Shaashua L, Benish M, Zmora N, Barshack I, Hoffman A, Ben-Eliyahu S, Zmora O (2010). Effect of beta-blocker combined with COX-2 inhibitor on colonic anastomosis in rats. Int J Colorectal Dis. doi: 10.1007\/s00384-010-0992-8","DOI":"10.1007\/s00384-010-0992-8"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-010-1039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00384-010-1039-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-010-1039-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:05:33Z","timestamp":1559059533000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00384-010-1039-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,6]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1007\/s00384-010-1039-x","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"value":"0179-1958","type":"print"},{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,6]]}}}